
CFRX
Healthcare · Biotechnology · $535,240 market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2023
EPS trend, 90 days to now · 0.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 14, 2023 | After the close | -0.66 | -0.50 | +24.2% |
| Aug 14, 2023 | After the close | -1.81 | -1.94 | -7.2% |
| May 15, 2023 | After the close | -10.83 | -0.69 | +93.6% |
| Mar 31, 2023 | After the close | -27.20 | -16.14 | +40.7% |
| Nov 14, 2022 | After the close | -18.40 | -18.40 | 0.0% |
| Aug 15, 2022 | After the close | -29.80 | -36.80 | -23.5% |
| May 16, 2022 | After the close | -24.96 | -40.80 | -63.5% |
| Mar 24, 2022 | After the close | -22.00 | -8.80 | +60.0% |
| Nov 15, 2021 | After the close | -22.60 | -10.40 | +54.0% |
| Aug 13, 2021 | After the close | -22.40 | -11.20 | +50.0% |
| May 14, 2021 | After the close | -17.60 | -14.40 | +18.2% |
| Mar 30, 2021 | After the close | -24.48 | -18.40 | +24.8% |
| Nov 13, 2020 | After the close | -30.56 |
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational…
| 9.60 |
| +131.4% |
| Aug 14, 2020 | After the close | -29.44 | -70.40 | -139.1% |
| May 15, 2020 | After the close | -49.60 | -39.20 | +21.0% |
| Mar 18, 2020 | After the close | -66.40 | -88.80 | -33.7% |
| Nov 12, 2019 | After the close | -62.00 | -56.00 | +9.7% |
| Aug 9, 2019 | After the close | -68.80 | -88.00 | -27.9% |
| May 10, 2019 | After the close | -82.00 | 120.00 | +246.3% |
| Mar 14, 2019 | After the close | -76.80 | 56.00 | +172.9% |
| Nov 8, 2018 | After the close | -78.40 | -48.00 | +38.8% |
| Aug 9, 2018 | After the close | -78.40 | -216.00 | -175.5% |
| May 10, 2018 | After the close | -72.80 | -72.00 | +1.1% |
| Mar 15, 2018 | After the close | -76.00 | -48.00 | +36.8% |